Online first
Research paper
Published online: 2024-12-16
The Concentration of Triglycerides is Significantly Associated with the Prevalence of Coronary Artery Disease in Pancreas Recipients with Type 1 Diabetes: A Cross-Sectional Study
1
, 2, 3, 1, 3
, 2, 3, 1, 3
Abstract
Objective: Coronary artery disease (CAD) and its complications significantly affect the post-transplant prognosis in pancreas recipients. This study aimed to evaluate the associations between CAD and its major risk factors (RFs) and to identify the strongest modifiable predictor of CAD in potential pancreas recipients with type 1 diabetes (T1D). Materials and methods: This is a prospective, crosssectional study. Patients with T1D qualified for simultaneous pancreas-kidney transplantation or pancreas transplantation alone were enrolled. The diagnosis of CAD was based on invasive coronary angiography. The major cardiovascular RFs included in the analyses were hypertension, lipid profile, obesity, and smoking. Results: The study population included 113 patients with a median age of 40 (35–46) years. The median duration of T1D was 26 years (23–32), and 61.9% of participants (n = 70) were on hemodialysis. CAD was found in 31 (27.4%) participants. Multivariate logistic regression analysis demonstrated that age (OR 1.159; 95% CI: 1.062–1.265, p = 0.001), the concentration of triglycerides (TG) (OR 4.534; 95% CI: 1.803–11.403, p = 0.001), and hemodialysis (OR 4.027; 95% CI: 1.13–14.358, p = 0.032) were independently associated with the prevalence of CAD in this cohort. Finally, the concentration of TG was the only modifiable RF that was independently associated with the prevalence of CAD. Conclusions: Fasting TG levels were positively associated with the prevalence of CAD in potential pancreas recipients with T1D. The concentration of TG has the potential to serve as a modifiable RF or at least as an important biomarker in this group and should be included in the cardiological pre-transplant assessment.
Keywords: type 1 diabetestriglyceridespancreas transplantationpancreas-kidney transplantationcoronary artery diseaserisk factors
References
- Gruessner AC, Gruessner RWG. Pancreas Transplantation of US and Non-US Cases from 2005 to 2014 as Reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud. 2016; 13(1): 35–58.
- Knight S, Vogel T, Friend P. Pancreas transplantation. Surgery (Oxford). 2023; 41(9): 616–622.
- Parajuli S, Bath NM, Aziz F, et al. More Than 25 Years of Pancreas Graft Survival After Simultaneous Pancreas and Kidney Transplantation: Experience From the World's Largest Series of Long-term Survivors. Transplantation. 2020; 104(6): 1287–1293.
- Gruessner A. A Decade of Pancreas Transplantation—A Registry Report. Uro. 2023; 3(2): 132–150.
- Senior PA. Glucose as a modifiable cause of atherosclerotic cardiovascular disease: Insights from type 1 diabetes and transplantation. Atherosclerosis. 2021; 335: 16–22.
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Risk Factors for Cardiovascular Disease in Type 1 Diabetes. Diabetes. 2016; 65(5): 1370–1379.
- Rawshani A, Rawshani A, Sattar N, et al. Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation. 2019; 139(16): 1900–1912.
- Solnica B, Sygitowicz G, Sitkiewicz D, et al. 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders. Arch Med Sci. 2024; 20(2): 357–374.
- Friedewald W, Levy R, Fredrickson D. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. Clin Chem. 1972; 18(6): 499–502.
- St Michel D, Donnelly T, Jackson T, et al. Assessing Pancreas Transplant Candidate Cardiac Disease: Preoperative Protocol Development at a Rapidly Growing Transplant Program. Methods Protoc. 2019; 2(4).
- Mangus RS, Powelson J, Kinsella SB, et al. Pretransplant coronary artery disease associated with worse clinical outcomes in pancreas transplantation. Clin Transplant. 2013; 27(4): E442–E447.
- Marques J, Pereira L, Messias A, et al. The burden of coronary heart disease in simultaneous pancreas-kidney transplantation: coronary angiography as a diagnostic method for all? - a retrospective study. J Bras Nefrol. 2022; 44(4): 522–526.
- Tuomilehto J, Borch-Johnsen K, Molarius A, et al. Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia. 1998; 41(7): 784–790.
- Giménez-Pérez G, Viñals C, Mata-Cases M, et al. Epidemiology of the first-ever cardiovascular event in people with type 1 diabetes: a retrospective cohort population-based study in Catalonia. Cardiovasc Diabetol. 2023; 22(1): 179.
- Harjutsalo V, Thomas MC, Forsblom C, et al. FinnDiane Study Group. Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes. Diabetes Obes Metab. 2018; 20(12): 2759–2767.
- Oliveira DC, Brito Junior FS, Fernandes RW, et al. Subclinical coronary artery disease in patients with type 1 Diabetes Mellitus undergoing hemodialysis. Arq Bras Cardiol. 2009; 93(1): 15–21.
- Kim J, Schulman-Marcus J, Watkins AC, et al. In-Hospital Cardiovascular Complications After Pancreas Transplantation in the United States from 2003 to 2012. Am J Cardiol. 2017; 120(4): 682–687.
- Tolonen N, Forsblom C, Thorn L, et al. FinnDiane Study Group. Relationship between lipid profiles and kidney function in patients with type 1 diabetes. Diabetologia. 2008; 51(1): 12–20.
- Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007; 115(4): 450–458.
- Wu Z, Gao J, Chen S, et al. Triglyceride levels and risk of cardiovascular disease and all-cause mortality in Chinese adults younger than 40 years old: a prospective cohort study. Cardiovasc Diagn Ther. 2024; 14(2): 240–250.
- Miller M, Cannon CP, Murphy SA, et al. PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008; 51(7): 724–730.
- Bosch J, Gerstein HC, Dagenais GR, et al. ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012; 367(4): 309–318.
- Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–188.
- Faergeman O, Holme I, Fayyad R, et al. Steering Committees of IDEAL and TNT Trials. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009; 104(4): 459–463.
- Schwartz GG, Abt M, Bao W, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015; 65(21): 2267–2275.
- Hero C, Svensson AM, Gidlund P, et al. LDL cholesterol is not a good marker of cardiovascular risk in Type 1 diabetes. Diabet Med. 2016; 33(3): 316–323.
- Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021; 42(47): 4791–4806.
- Drexel H, Tamargo J, Kaski JC, et al. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease? Eur Heart J Cardiovasc Pharmacother. 2023; 9(6): 570–582.
- Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013; 45(11): 1345–1352.
- Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013; 61(4): 427–436.
- Park JK, Bafna S, Forrest IS, et al. Phenome-wide Mendelian randomization study of plasma triglyceride levels and 2600 disease traits. Elife. 2023; 12.
- Colhoun HM, Otvos JD, Rubens MB, et al. Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes. Diabetes. 2002; 51(6): 1949–1956.
- Miller RG, Anderson SJ, Costacou T, et al. Risk stratification for 25-year cardiovascular disease incidence in type 1 diabetes: Tree-structured survival analysis of the Pittsburgh Epidemiology of Diabetes Complications study. Diab Vasc Dis Res. 2016; 13(4): 250–259.
- Wehinger A, Tancevski I, Schgoer W, et al. Phospholipid transfer protein augments apoptosis in THP-1-derived macrophages induced by lipolyzed hypertriglyceridemic plasma. Arterioscler Thromb Vasc Biol. 2007; 27(4): 908–915.
- Van Eck M, Zimmermann R, Groot PH, et al. Role of macrophage-derived lipoprotein lipase in lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2000; 20(9): E53–E62.
- Saraswathi V, Hasty AH. The role of lipolysis in mediating the proinflammatory effects of very low density lipoproteins in mouse peritoneal macrophages. J Lipid Res. 2006; 47(7): 1406–1415.
- Varbo A, Benn M, Tybjærg-Hansen A, et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013; 128(12): 1298–1309.
- Tolonen N, Forsblom C, Mäkinen VP, et al. FinnDiane Study Group, FinnDiane Study Group, FinnDiane Study Group, Finnish Diabetic Nephropathy Study Group, FinnDiane Study Group, FinnDiane Study Group. Different lipid variables predict incident coronary artery disease in patients with type 1 diabetes with or without diabetic nephropathy: the FinnDiane study. Diabetes Care. 2014; 37(8): 2374–2382.